{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:42:50Z","timestamp":1793216570311,"version":"4.5.0"},"reference-count":52,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi230010-4\"><jats:title>Importance<\/jats:title><jats:p>The number of older adults with head and neck squamous cell carcinoma (HNSCC) is increasing, and these patients are underrepresented in clinical trials. It is unclear whether the addition of chemotherapy or cetuximab to radiotherapy is associated with improved survival in older adults with HNSCC.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230010-5\"><jats:title>Objective<\/jats:title><jats:p>To examine whether the addition of chemotherapy or cetuximab to definitive radiotherapy is associated with improved survival in patients with locoregionally advanced (LA) HNSCC.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230010-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy (SENIOR) study is an international, multicenter cohort study including older adults (\u226565 years) with LA-HNSCCs of the oral cavity, oropharynx\/hypopharynx, or larynx treated with definitive radiotherapy, either alone or with concomitant systemic treatment, between January 2005 and December 2019 at 12 academic centers in the US and Europe. Data analysis was conducted from June 4 to August 10, 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230010-7\"><jats:title>Interventions<\/jats:title><jats:p>All patients underwent definitive radiotherapy alone or with concomitant systemic treatment.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230010-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was overall survival. Secondary outcomes included progression-free survival and locoregional failure rate.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230010-9\"><jats:title>Results<\/jats:title><jats:p>Among the 1044 patients (734 men [70.3%]; median [IQR] age, 73 [69-78] years) included in this study, 234 patients (22.4%) were treated with radiotherapy alone and 810 patients (77.6%) received concomitant systemic treatment with chemotherapy (677 [64.8%]) or cetuximab (133 [12.7%]). Using inverse probability weighting to attribute for selection bias, chemoradiation was associated with longer overall survival than radiotherapy alone (hazard ratio [HR], 0.61; 95% CI, 0.48-0.77; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), whereas cetuximab-based bioradiotherapy was not (HR, 0.94; 95% CI, 0.70-1.27; <jats:italic>P<\/jats:italic>\u2009=\u2009.70). Progression-free survival was also longer after the addition of chemotherapy (HR, 0.65; 95% CI, 0.52-0.81; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), while the locoregional failure rate was not significantly different (subhazard ratio, 0.62; 95% CI, 0.30-1.26; <jats:italic>P<\/jats:italic>\u2009=\u2009.19). The survival benefit of the chemoradiation group was present in patients up to age 80 years (65-69 years: HR, 0.52; 95% CI, 0.33-0.82; 70-79 years: HR, 0.60; 95% CI, 0.43-0.85), but was absent in patients aged 80 years or older (HR, 0.89; 95% CI, 0.56-1.41).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230010-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cohort study of older adults with LA- HNSCC, chemoradiation, but not cetuximab-based bioradiotherapy, was associated with longer survival compared with radiotherapy alone.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.0090","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T16:08:52Z","timestamp":1676909332000},"page":"e230090","source":"Crossref","is-referenced-by-count":33,"title":["Evaluation of Concomitant Systemic Treatment in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Radiotherapy"],"prefix":"10.1001","volume":"6","author":[{"given":"Alexander","family":"R\u00fchle","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Freiburg\u2013Medical Center, Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Marschner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany"},{"name":"DKTK Partner Site Munich, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlen","family":"Haderlein","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Fabian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Weymann","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center-University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Behrens","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center-University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Senger","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Germany, Berlin, Germany"},{"name":"DKTK Partner Site Berlin, DKFZ, Neuenheimer Feld 280, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Dickstein","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kraft","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"von der Gr\u00fcn","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany"},{"name":"DKTK Partner Site Frankfurt, German Cancer Research Center, Heidelberg, Germany"},{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Aquino-Michaels","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Domschikowski","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Bickel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alev","family":"Altay-Langguth","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany"},{"name":"DKTK Partner Site Frankfurt, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goda","family":"Kalinauskaite","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Germany, Berlin, Germany"},{"name":"DKTK Partner Site Berlin, DKFZ, Neuenheimer Feld 280, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Lewitzki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Ferentinos","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, German Oncology Center, European University of Cyprus, Limassol, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Freiburg\u2013Medical Center, Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany"},{"name":"Department of Radiation Oncology, German Oncology Center, European University of Cyprus, Limassol, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Schnellhardt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Haehl","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany"},{"name":"DKTK Partner Site Munich, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon K.B.","family":"Spohn","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Freiburg\u2013Medical Center, Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Freiburg\u2013Medical Center, Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Z\u00f6ller","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center-University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Budach","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Germany, Berlin, Germany"},{"name":"DKTK Partner Site Berlin, DKFZ, Neuenheimer Feld 280, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany"},{"name":"DKTK Partner Site Munich, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bakst","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Radiation Therapy, University Medical Center Mainz, Mainz, Germany"},{"name":"DKTK Partner Site Mainz, German Cancer DKFZ, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Schmidberger","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Radiation Therapy, University Medical Center Mainz, Mainz, Germany"},{"name":"DKTK Partner Site Mainz, German Cancer DKFZ, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Freiburg\u2013Medical Center, Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Balermpas","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Stromberger","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Germany, Berlin, Germany"},{"name":"DKTK Partner Site Berlin, DKFZ, Neuenheimer Feld 280, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils H.","family":"Nicolay","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Freiburg\u2013Medical Center, Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany"},{"name":"Department of Radiation Oncology, University of Leipzig, Leipzig, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"issue":"6","key":"zoi230010r1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.v68.6","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"zoi230010r2","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","article-title":"Future of cancer incidence in the United States: burdens upon an aging, changing nation.","volume":"27","author":"Smith","year":"2009","journal-title":"J Clin Oncol"},{"key":"zoi230010r3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.","volume":"156","author":"Lacas","year":"2021","journal-title":"Radiother Oncol"},{"issue":"1","key":"zoi230010r4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi230010r5","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1007\/s00520-020-05932-w","article-title":"The course of health-related quality of life from diagnosis to two years follow-up in patients with oropharyngeal cancer: does HPV status matter?","volume":"29","author":"Korsten","year":"2021","journal-title":"Support Care Cancer"},{"issue":"14","key":"zoi230010r6","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1002\/cncr.v124.14","article-title":"Increasing prevalence of human papillomavirus\u2013positive oropharyngeal cancers among older adults.","volume":"124","author":"Windon","year":"2018","journal-title":"Cancer"},{"key":"zoi230010r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104687","article-title":"A new face of the HPV epidemic: oropharyngeal cancer in the elderly.","volume":"109","author":"Dickstein","year":"2020","journal-title":"Oral Oncol"},{"issue":"1","key":"zoi230010r8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijrobp.2014.01.053","article-title":"Effectiveness of chemoradiation for head and neck cancer in an older patient population.","volume":"89","author":"VanderWalde","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"zoi230010r9","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/cncr.29956","article-title":"Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.","volume":"122","author":"Amini","year":"2016","journal-title":"Cancer"},{"key":"zoi230010r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.104472","article-title":"Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence.","volume":"99","author":"Lu","year":"2019","journal-title":"Oral Oncol"},{"issue":"5","key":"zoi230010r12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"7","key":"zoi230010r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v074.i07","article-title":"Imputation with the R Package VIM.","volume":"74","author":"Kowarik","year":"2016","journal-title":"J Stat Softw"},{"issue":"2","key":"zoi230010r14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals.","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"issue":"3","key":"zoi230010r15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018174","article-title":"Weight trimming and propensity score weighting.","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"zoi230010r16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20f13681","article-title":"Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets.","volume":"81","author":"Andrade","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"zoi230010r17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"446","key":"zoi230010r18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"11","key":"zoi230010r19","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.3390\/cancers14112809","article-title":"Management of older adults with locally advanced head and neck cancer.","volume":"14","author":"Dickstein","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"zoi230010r20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1634\/theoncologist.2012-0427","article-title":"Treatment of older patients with head and neck cancer: a review.","volume":"18","author":"VanderWalde","year":"2013","journal-title":"Oncologist"},{"issue":"3","key":"zoi230010r21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cancers14030472","article-title":"Head and neck squamous cell carcinoma in elderly patients: role of radiotherapy and chemotherapy.","volume":"14","author":"Fasano","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"zoi230010r22","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/hed.24739","article-title":"Survival impact of induction chemotherapy in advanced head and neck cancer: a National Cancer Database analysis.","volume":"39","author":"Stokes","year":"2017","journal-title":"Head Neck"},{"issue":"2","key":"zoi230010r23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.critrevonc.2014.02.002","article-title":"A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? on behalf of the REFCOR (French rare head and neck cancer network).","volume":"91","author":"Cerda","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"zoi230010r24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/cancers12020258","article-title":"Outcomes for elderly patients aged 70 to 80 years or older with locally advanced oral cavity squamous cell carcinoma: a propensity score\u2013matched, nationwide, oldest old patient-based cohort study.","volume":"12","author":"Shia","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"zoi230010r25","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.radonc.2009.07.015","article-title":"Oral cavity squamous cell carcinoma in 260 patients aged 80 years or more.","volume":"93","author":"Ortholan","year":"2009","journal-title":"Radiother Oncol"},{"issue":"11","key":"zoi230010r26","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/cncr.v113:11","article-title":"Head and neck squamous cell carcinoma in patients aged =80 years: patterns of care and survival.","volume":"113","author":"Italiano","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"zoi230010r27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13014-020-1481-z","article-title":"Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?","volume":"15","author":"Haehl","year":"2020","journal-title":"Radiat Oncol"},{"issue":"1","key":"zoi230010r28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"issue":"5","key":"zoi230010r29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.oraloncology.2015.02.097","article-title":"Predictive factors of survival and treatment tolerance in older patients treated with chemotherapy and radiotherapy for locally advanced head and neck cancer.","volume":"51","author":"Bahig","year":"2015","journal-title":"Oral Oncol"},{"issue":"6","key":"zoi230010r30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.amjoto.2013.07.010","article-title":"Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.","volume":"34","author":"Daly","year":"2013","journal-title":"Am J Otolaryngol"},{"issue":"7","key":"zoi230010r31","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1007\/s00405-021-07211-8","article-title":"Causes of long-term mortality in patients with head and neck squamous cell carcinomas.","volume":"279","author":"Lop","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"7","key":"zoi230010r32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"issue":"29","key":"zoi230010r33","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1200\/JCO.2015.61.3836","article-title":"Advances in supportive care for late effects of head and neck cancer.","volume":"33","author":"Murphy","year":"2015","journal-title":"J Clin Oncol"},{"key":"zoi230010r34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.723716","article-title":"Patterns-of-care analysis for radiotherapy of elderly head-and-neck cancer patients: a trinational survey in Germany, Austria and Switzerland.","volume":"11","author":"Haehl","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"zoi230010r35","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1634\/theoncologist.2017-0015","article-title":"Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non\u2013nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data.","volume":"22","author":"Szturz","year":"2017","journal-title":"Oncologist"},{"issue":"18","key":"zoi230010r36","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.21.01293","article-title":"Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II\/III randomized controlled trial.","volume":"40","author":"Kiyota","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi230010r37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","article-title":"Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.","volume":"12","author":"Nutting","year":"2011","journal-title":"Lancet Oncol"},{"issue":"10166","key":"zoi230010r38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"issue":"10166","key":"zoi230010r39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus\u2013positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"zoi230010r40","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomised trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01)\u2014a Trans-Tasman Radiation Oncology Group study.","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi230010r41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.oraloncology.2018.09.023","article-title":"Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: analysis of the SEER-Medicare linked database.","volume":"86","author":"Zandberg","year":"2018","journal-title":"Oral Oncol"},{"issue":"1","key":"zoi230010r42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/s12885-020-07297-z","article-title":"Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).","volume":"20","author":"Lee","year":"2020","journal-title":"BMC Cancer"},{"issue":"11","key":"zoi230010r44","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi230010r45","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ijrobp.2014.12.034","article-title":"Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU\/mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.","volume":"91","author":"Budach","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"zoi230010r46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0360-3016(00)00408-9","article-title":"The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.","volume":"47","author":"Suntharalingam","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"zoi230010r47","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/annonc\/mdm088","article-title":"Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer.","volume":"18","author":"Agarwala","year":"2007","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi230010r48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(11)70346-1","article-title":"Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.","volume":"13","author":"Bourhis","year":"2012","journal-title":"Lancet Oncol"},{"issue":"13","key":"zoi230010r49","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.3390\/cancers14133290","article-title":"Effectiveness of geriatric assessment\u2013driven interventions on survival and functional and nutritional status in older patients with head and neck cancer: a randomized controlled trial (EGeSOR).","volume":"14","author":"Paillaud","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"zoi230010r50","doi-asserted-by":"publisher","first-page":"e214158","DOI":"10.1001\/jamaoncol.2021.4158","article-title":"Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial.","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"key":"zoi230010r51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.radonc.2020.11.023","article-title":"Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation.","volume":"154","author":"R\u00fchle","year":"2021","journal-title":"Radiother Oncol"},{"issue":"1","key":"zoi230010r52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ijrobp.2009.10.052","article-title":"Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study.","volume":"79","author":"Huang","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi230010r11","first-page":"22","volume-title":"International Union Against Cancer (UICC): TNM Classification of Malignant Tumours","author":"Sobin","year":"2009","edition":"7th ed"},{"key":"zoi230010r43","unstructured":"National Comprehensive Cancer Network. Head and Neck Cancer (Version 2.2022). 2022. Accessed July 22, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2801648\/rhle_2023_oi_230010_1676273937.7384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T16:08:58Z","timestamp":1676909338000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2801648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.0090","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]}}}